Condition
Disorder of Immune Reconstitution
Total Trials
3
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Early P 1 (1)
P 1 (1)
P 2 (1)
Trial Status
Unknown3
Clinical Trials (3)
Showing 3 of 3 trials
NCT05872659Early Phase 1Unknown
Mesenchymal Stem Cells for Immune Non-responder Patients With HIV Infection
NCT02648516Phase 1Unknown
Safety and Efficacy of Allogenic Adoptive Immune Therapy for Immune Reconstitution in Chronic HIV-1 Infected Patients
NCT01213186Phase 2Unknown
Umbilical Cord Mesenchymal Stem Cells for Immune Reconstitution in HIV-infected Patients
Showing all 3 trials